Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection

BACKGROUND: Chronic HBV infects 350 million people causing cancer and liver failure. We aimed to assess the safety and efficacy of plasmid DNA (pSG2.HBs) vaccine, followed by recombinant modified vaccinia virus Ankara (MVA.HBs), encoding the surface antigen of HBV as therapy for chronic HBV. A secon...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavenaugh, James S., Awi, Dorka, Mendy, Maimuna, Hill, Adrian V. S., Whittle, Hilton, McConkey, Samuel J.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039644/
https://www.ncbi.nlm.nih.gov/pubmed/21347224
http://dx.doi.org/10.1371/journal.pone.0014626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039644/
https://www.ncbi.nlm.nih.gov/pubmed/21347224
http://dx.doi.org/10.1371/journal.pone.0014626

Ejemplares similares